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GLOSSARY  
Following abbreviations are used in this thesis 
 
NPs ……………. Nanoparticles 
Aln-Cur-NPs…...Alendronate conjugated curcumin nanoparticles 
Cur-NPs………...Curcumin nanoparticles 
CLSM…………. Confocal laser scanning microscopy 
OPG………….... Osteoprotegrin 
M-CSF………… Macrophage colony stimulating factor 
TGF-β…………. Transforming growth factor-β 
RANKL………...Receptor activator of NF- κB ligand 
PTHrP…………. Parathyroid hormone related protein 
PDGF…………...Platelet derived growth factor 
IGF……………...Insulin like growth factor 
HPLC…………...High performance liquid chromatography 
LC…………….... Loading capacity 
IL………………. Interleukin 
SRE……………. Skeletal related events 
CTSK……………Cathepsin K 
BMP-2…………. Bone morphogenetic protein 
PEG…………......Poly ethylene glycol 
MTTT…………...3-(4,5-Dimethylthiazole-2-Yl)-2,5-Diphenyltetrazolium Bromide
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THESIS CHAPTERS ABSTRACTS 
            CHAPTER 1 
It is about thesis introduction and thesis chapters. It also includes historical perspective of 
breast cancer bone metastasis and aims and objectives of my work.        
             CHAPTER 2 
Abstract: Background: Breast cancer is the most frequently diagnosed malignancy in women 
worldwide. Breast cancer tends to metastasize to bone. Around 70% of the breast cancer patients 
eventually develop bone metastasis. After the bone invasion, metastatic cells alter the balance between 
osteoblastic and osteoclastic activities, leading to skeletal complications, characterized by pain and 
pathological fractures and hence worsening the patient's quality of life. Once tumor invades the bone, 
it is hard to treat it with the so-far available treatments options (e.g. bisphosphonates and denosumab). 
Bone metastasis should be essentially controlled, in cancer treatment and there is a strong need to 
explore new, more efficient therapeutic targets. This review discusses the bone physiological processes 
and the recent advances in exploring different pathways involved in bone metastasis. Furthermore, 
some novel treatment options, which are under preclinical and clinical investigations, are highlighted. 
Conclusion: A deeper understanding of these metastatic pathways can provide oncology researchers 
with novel avenues for treating bone metastasis, one of the main challenges to cure breast cancer. The 
restoration of healthy bone environment will not only improve the patient's quality of life but also 
reduces the tumor burden. 
Keywords: Bone Metastasis, Targeted strategies, Osteoblasts, Osteoclasts, Bone resorption, Novel 
targets, RANKL/RANK,  
 
            CHAPTER 3 
Abstract 
The most common cancer among women is breast cancer. According to an estimation by breast cancer 
network Australia, 18,087 women will be diagnosed with breast cancer in 2018. About 70% of the 
breast cancer patients develop bone metastasis. In pre-clinical investigations, curcumin reported to be 
non-toxic even at doses of 12 g per day. However, with this high dose of curcumin, only 50 nM plasma 
concentration is achieved. The reason for this low plasma concentration of curcumin is low water 
solubility and instability. We have previously developed a new nanoformulation of curcumin (Cur-NP) 
with enhanced physicochemical properties as well as improved antitumor activity in breast cancer cell 
lines. Furthermore, we have formulated alendronate-conjugated curcumin nanoparticles (Aln-Cur-NPs) 
for the targeted delivery of the drug payload (curcumin in this project) to the bone. This project aims to 
investigate the in vitro biological effects of Aln-Cur-NPs that are developed to prevent breast cancer 
bone metastasis.  The loading capacity and particle size of the new batch fabricated for this study was 
determined and was shown to be consistent with previous batches of Aln-Cur-NPs and Cur-NPs. The 
loading capacity was found to be 4% and 5.7%, and the size was 28 nm and 23 nm for Aln-Cur-NP and 
Cur-NP, respectively. In vitro anti-tumor activity of the curcumin nanoparticles with and without 
alendronate conjugation, was evaluated in three different breast cancer cell lines and reported as IC50 
values equivalent to the concentration of curcumin. A significantly higher antitumor activity was 
observed for Aln-Cur-NP compared to Cur-NP with IC50 values of 13.9, 22.2 and 7.7 µg/mL for MCF-
7, MDA-MB-231 and SK-BR-3, respectively. This study showed the enhanced anticancer activity of 
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curcumin nanoparticles conjugated with alendronate compared to Cur-NPs, which strongly supports 
the synergistic effect of curcumin/bisphosphonates combination considering the similar amount of 
uptaken curcumin by the cancer cells for both nanoparticle formulations. The impact of nanoparticles 
on the viability of MDA-MB-231 cells was also investigated using recording time lapse image 
technology by IncuCyte® Zoom over two days. It was demonstrated that the uptake of raw 
curcumin was much less, and it precipitated outside the cells while, curcumin encapsulated in 
nanoparticles was effectively uptaken by the cancer cells. In the same experiment, we observed 
that Aln-Cur-NPs reduced the viability of the cells more effectively than Cur-NPs and raw 
curcumin. 
The uptake of Aln-Cur-NPs and Cur-NPs in nucleus and cytoplasm in MDA-MB-231after 24 hours of 
treatment was revealed by Confocal Scanning Laser Microscopy. The qualitative analysis of confocal 
images showed higher uptake for Aln-Cur-NPs compared to raw curcumin (p ˂0.0001) and no uptake 
for the untreated (PBS) control. Parathyroid Hormone Related Protein (PTHrP) release is increased by 
cancer cells in bone microenvironment and promotes osteoclastic activity and contribute to osteolytic 
bone metastases. The effect of our Nanoparticles on the release of PTHrP was determined by PTHrP 
ELISA assay for quantitative measurement of human PTHrP concentration released by MDA-MB-231 
cells. MDA-MB-231 cells were treated with alendronate-modified and non-modified curcumin 
nanoparticles. Results showed a reduction in the release of PTHrP by MDA-MB-231 cell lines by both 
curcumin nanoparticles compared to the negative control (PBS-treated). Cur-NP and Aln-Cur-NPs 
showed twice higher activity in reducing the release of PTHrP compared to raw curcumin. These results 
suggested the possibility of reducing osteolytic activity of the cancer cells in bone metastasis. These 
preliminary data suggest Aln-Cur-NPs can offer promises in preventing and treating breast cancer bone 
metastases.   
 
           CHAPTER 4 
             It includes the conclusion and future directions.. 
           CHAPTER 5 
            It includes appendices related to my publications and conference presentations. 
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CHAPTER 1 
INTRODUCTION 
1.1. Thesis Organization 
This thesis is comprised of four chapters. Chapter 1 encompasses the introduction of thesis. It also 
includes aims and objective of my work. Chapter 2 includes a review article which has already been 
published in the journal “Current Pharmaceutical design”. The publication’s title is: “Different targeting 
strategies to prevent breast cancer bone metastases”. This chapter includes introduction to breast cancer 
bone metastases, normal bone functioning, mechanism of breast cancer bone metastases, treatment 
strategies for breast cancer bone metastases, novel treatment strategies for preventing breast cancer 
bone metastases.  
Chapter 3 is comprised of the manuscript of the paper which we are intended to publish soon on the 
topic “The pharmacological evaluation of an advanced formulation of curcumin to prevent breast cancer 
bone metastases’. This chapter includes the In-vitro evaluation of Alendronate –conjugated curcumin 
nanoparticles (Aln-Cur-NPs). In-vitro experiments include drug loading capacity measurement, 
anticancer activity of Aln-Cur-NPs, uptake studies of nanoparticles using confocal laser scanning 
microscopy (CLSM) and live cell analysis using IncuCyte. Chapter 4 is about conclusion, future 
directions and final remarks. Chapter 5 includes different appendices attached to thesis. 
1.2. Historical Perspective  
Cancer that spreads beyond breast to other organs is called breast cancer. According to a survey 
conducted by Australian Breast Cancer Network, 15,600 women and 145 men were diagnosed with 
breast cancer in 2015. It’s almost 42 women each day were diagnosed having breast cancer. For women 
of 85 years old age group, 1 in 8 women was diagnosed to have breast cancer. In 2020, this number is 
expected to increase up to 17,210 women with breast cancer (1). About 90-95% of breast cancer patients 
are diagnosed in early stages. Breast cancer tends to metastasize to distant organs.  Almost 20-30% of 
the breast cancer patients develop metastatic disease (2). 
Bone is the most common metastatic organ (1). About 70% of metastatic patients develop bone 
metastases. Bone metastases is associated with skeletal morbidity (2). Furthermore, Bone is the storage 
area for different growth factors like transforming growth factor (TGF-β), insulin-like growth factor 
(IGF)-I and II, fibroblasts growth factor (FGF)-I and II and platelet derived growth factors. Once these 
growth factors get stimulated by cancer cells they further support the tumor growth in bone. About half 
of the patients suffer skeletal related events (SREs). SREs include spinal cord compression, pathological 
fractures and pain requiring radiation therapy or surgery (3, 4).   High blood flow to the bone marrow 
and bone environment favors the residency and growth of cancer cells in the bone (5). 
Currently available treatment options for bone metastases are bisphosphonates and denosumab. Other 
than these, radiopharmaceuticals, radiotherapy and surgery are of clinical value in managing bone 
metastases. Currently available treatment options focus on improving patient’s quality of life by 
improving functional independence, preventing further SREs, managing pain and reducing pain. 
Unfortunately no preventive treatment is available (6).    
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AIMS & OBJECTIVE 
Once breast cancer spreads to the bones it is incurable, thus there is an absolute need for a preventative 
treatment against bone metastasis. Curcumin, a non-toxic plant extract has recently attracted much 
attention in medicine due to its remarkable therapeutic actions. We have demonstrated that formulating 
curcumin in nanoparticles significantly promotes its anti-cancer activities. In this project, we will extend 
this research by investigating the possible combination therapy to prevent breast cancer cells from 
spreading to the bones using curcumin and bisphosphonates, which are well-known anti-bone-
resorptive agents currently used in palliative treatment in patients with bone metastatic cancer. The 
project will test the hypothesis that curcumin nanoparticles coated with bisphosphonates will reduce the 
risk of breast cancer bone metastasis. 
 
The overall objectives of this research are: 
 
• Preparation of nanoparticles following our previous work.  
• Determination of loading capacity of nanoparticles. 
• Determination of anti-proliferative effects of nanoparticles. 
• Investigation of uptake of nanoparticles by MDA-MB-231 cells. 
• Determining the inhibitory effect of curcumin nanoparticles on the release of PTHrP peptide. 
 
 
Nanoparticles are safe and effective in cancer treatment. Nanoparticles also provide targeted therapy to 
cancer cells with direct killing of cancer cells without damaging the healthy cells. That is why they are 
most widely researched as a treatment option for cancer.  
Firstly, curcumin nanoparticles were made according to our previous work.  Our first target was to 
determine the loading capacity of nanoparticles and loading of curcumin in each nanoparticle should 
be determined. 
Secondly, anti-proliferative effect of curcumin nanoparticles should be evaluated to determine IC50 
values of curcumin nanoparticles.  
Thirdly, to assure cellular internalization of nanoparticles, up-take studies were done. 
Fourthly, effect of our nanoparticles was determined on the release of PTHrP from cancer cells.  
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CHAPTER 2 
DIFFERENT TARGETING STRATEGIES FOR TREATING 
BREAST CANCER BONE METASTASES. 
 
 
This chapter has been published in current pharmaceutical design as   
Irshad I, Varamini P. Different Targeting Strategies for Treating Breast Cancer Bone 
Metastases. Current pharmaceutical design. 2018 Jun 19. 
 
 
 
 
 
 
 
 
 
13 
 
DIFFERENT TARGETING STRATEGIES FOR TREATING BREAST CANCER 
BONE METASTASES. 
Breast Cancer Bone Metastasis: Different targeting strategies. 
Iram Irshad, Pegah Varamini* 
Faculty of Pharmacy, The University of Sydney, Sydney, NSW 2006, Australia. 
*Address correspondence to Dr Pegah Varamini: Faculty of Pharmacy (A16), The University of Sydney, NSW, 
2006 Australia. T: +61 2 8627 0809 F: +61 2 9351 4391 E: pegah.varamini@sydney.edu.au 
Abstract 
Abstract: Background: Breast cancer is the most frequently diagnosed malignancy in women worldwide. Breast 
cancer tends to metastasize to bone. Around 70% of the breast cancer patients eventually develop bone metastasis. 
After the bone invasion, metastatic cells alter the balance between osteoblastic and osteoclastic activities, leading 
to skeletal complications, characterized by pain and pathological fractures and hence worsening the patient's 
quality of life. Once tumor invades the bone, it is hard to treat it with, the so-far available treatments options (e.g. 
bisphosphonates and denosumab). Bone metastasis should be essentially controlled, in cancer treatment and there 
is a strong need to explore new, more efficient therapeutic targets. This review discusses the bone physiological 
processes and the recent advances in exploring different pathways involved in bone metastasis. Furthermore, some 
novel treatment options, which are under preclinical and clinical investigations, are highlighted. Conclusion: A 
deeper understanding of these metastatic pathways can provide oncology researchers with novel avenues for 
treating bone metastasis, one of the main challenges to cure breast cancer. The restoration of healthy bone 
environment will not only improve the patient's quality of life but also reduces the tumor burden. 
 
Keywords: Bone Metastasis, Targeted strategies, Osteoblasts, Osteoclasts, Bone resorption, Novel targets, 
RANKL/RANK,  
 
1. INTRODUCTION 
According to the Australian Institute of health and welfare 2017 report, 17730 Australians (17,586 of women and 
144 of men) are diagnosed with breast cancer and this number will increase to 18,235 Australians by 2018. Around 
3,000 patients died of breast cancer in 2017 (1), mainly due to advanced breast cancer. Patients with advanced 
breast cancer disease undergo aggressive therapy and most of them experience severe side effects. Roughly, 70% 
of metastatic breast cancer  patients develop bone metastasis, which may be complicated or uncomplicated bone 
metastasis. Uncomplicated bone metastasis can be characterized as the metastasis involving painful bone but not 
associated with existing pathologic fracture, spinal cord compression or cauda equina compression, while 
complicated bone metastasis is characterized by pathological fractures and spinal cord and cauda equina 
compression (2) (Fig. 1.1). Sometimes those associated with soft tissue components or those within weight bearing 
bones at high risk of fracture are also considered complicated. Bone metastases result in skeletal-related events 
(SREs) that can be described as spinal cord compression hypercalcemia, pathological fractures (excluding 
significant traumas), necessity for surgery to bone or bone radiation therapy (3). The microenvironment, where 
bone linked with bone marrow is ideal for tumor growth (4). Transcriptional analysis showed the involvement of 
gene for chemokines (CXCR4) involved in homing, matrix metalloproteinases (MMPs) involved in invasion, 
fibroblast growth factor (FGF) involved in angiogenesis, Interleukin-11(IL-11) and osteopontin (OPN) involved 
in osteolysis. It was shown that tumor cells that cause bone metastasis are characterized to invade healthy bone 
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tissue, increasing their multiplication and causing skeletal destruction (5, 6). This ongoing process eventually 
leads to an increase in bone pain, immobilization and progressively worsening the quality of life (7). 
This review will first provide an insight into the healthy bone physiological processes. Subsequently, mechanisms 
involved in breast cancer metastasis to bone in addition to some novel targets and treatment options that are under 
investigation will also be discussed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. NORMAL BONE FUNCTIONS 
Bone constitutes human skeleton. Human skeleton has structural and locomotor functions as well as being a 
calcium reservoir. During growth, the bone size is increased. Bone mineralization occurs during childhood and 
adolescence period (8).  
 
2.1. Modelling 
Through modelling the bones are shaped and adapt to load bearing and other influences. Modeling leads to bone 
mass, size and geometrical changes.   
 
2.2. Remodelling 
Microfracture repair happens regularly in normal individuals throughout their lives. This involves existing bone 
resorption, new bone deposition and mineralization. The whole process is called remodeling. An adult’s skeleton 
undergoes complete remodeling every decade. Bone remodeling regulation is crucial to explain bone metastasis 
as malignant tumor exploit these pathways to boost cancer growth and bone destruction. Bone remodeling 
involves the contribution of 2 types of cells including 1) osteoblasts liable for bone matrix production, 
mineralization, and remodeling process initiation and 2) osteoclasts accountable for bone resorption. 
 
2.3. Bone Formation and Resorption  
Bone growth, modelling and remodeling are based on bone formation and bone growth. Osteoblasts are 
responsible for bone formation.  
 
 2.3.1. Osteoblasts  
Osteoblasts contribute to the synthesis and mineralization of osteoid. Osteoid is a material responsible for bone 
shape, hardiness, and resilience. Some parameters that can be used to measure bone formation include 1) osteoid 
components like osteonectin, osteopontin and osteocalcin and 2) bone-specific alkaline phosphatase (BSAP). 
 
2.3.2. Osteocytes 
Osteoblasts which get captured into the new bone matrix (9, 10) are named as osteocytes. Osteocytes constitute 
90% of bone cells and are developed from osteoblasts who have completed their role in bone formation. 
Fig. (1.1). Changes in the bone structure from healthy bone tissue (A) to pathological fractures due to the cancer 
cell invasion and bone metastasis (D). 
Healthy bone Bone metastasis Pathological fractures Spongy bone after tumor 
invasion 
A B C D 
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Osteocytes develop into the osteocyte-osteoclast-osteoblast network system. Osteocytes are responsible for 
healing microfractures and harmonize remodeling (11). When microfracture occurs, osteocytes undergo apoptosis 
and sends signals to osteoclasts to begin bone resorption and remodeling. Osteocytes have regulatory roles on 
osteoclasts (8). 
 
2.3.3. Osteoclasts 
Osteoclasts execute bone resorption through the fusion to the bone, constituting a ring of firm junctions that are 
regulated by  α5β3 integrins (12). After binding, osteoclasts secrete acids and proteases (e.g., lysosomal 
cathepsins, MMPs phosphatases). Acids dissolve hydroxyapatite from bone and cathepsin, in contact with MMPs, 
degrades the collagen matrix. Osteoclasts endocytose debris from bone degradation. Later, osteoclasts discharge 
their content (high levels of calcium, magnesium, phosphates and products of collagen) into the blood stream and 
thus can be used to determine the value of overall bone resorptive activity of serum or urine. Osteoclasts 
differentiation is critically effected by receptor activator of nuclear factor-κB (RANK) ligand and macrophage 
colony-stimulating factor (M-CSF) (8). 
 
2.3.4. Mechanism of Normal Bone Remodeling 
In normal bone remodeling, osteoblasts express RANKL (NF- κB ligand) that binds to RANK on the surface of 
osteoclasts and their precursors. This binding regulates the osteoclasts differentiation from their precursors. 
Osteoclasts activation and survival lead to increased bone resorption. However, osteoblasts secrete osteoprotegrin 
(OPG) that inhibit excessive bone resorption by binding to RANKL and prevent binding with RANK. Hence, the 
balance between RANKL/Osteoprotegrin expression determines the bone mass in both normal and disease state 
(13).   Osteoblasts and osteoclasts are the basic units of normal bone remodeling (Fig. 1.2A). Osteoblasts are 
derived from mesenchymal stem cells under control of osteoblastic transcription factor called Runx2. 
Mononuclear myeloid precursors are fused to form pre-osteoclast. Pre-osteoclasts are differentiated into activated, 
multinuclear osteoclasts. This differentiation is controlled by colony-stimulating factor (M-CSF) and RANKL 
(receptor activator for NF- κB ligand). After activation, osteoclasts get adhered to bone and cause degradation of 
bone. Osteoblasts also produce a decoy receptor to RANKL called osteoprotegerin (OPG). The RANKL to OPG 
ratio is determinant of osteoclast activity. Bone lining cells and osteocytes also constitute osteoblastic lineage. 
 
3. CANCER BONE METASTASES 
 
3.1. Mechanism of Bone Metastasis 
After invading the bone marrow microenvironment (Fig. 1.2B) tumor cells disrupt the RANKL/osteoprotegrin 
(OPG) expression balance that leads to the over-production of osteoclasts. Additionally, tumor cells induce 
angiogenesis that enhances bone resorption and makes the bone tissue irregular and weak, causes abnormal bone 
formation via osteoblasts (14, 15), structural malformation, fracture and bone pain (16). Bone resorption is 
responsible for the release of various factors such as transforming growth factor (TGF-β and IGF1) and calcium. 
These further aggravate tumor growth and deregulation of RANKL/OPG expression. This is a vicious tumor 
growth cycle where increased bone resorption reinforces more tumor growth and vice versa (17). Relocation of 
cancer cells to the bone disturbs the normal cycle of the bone turnover, forms lytic, sclerotic tissue or mixed 
metastasis, which leads to substantial pain and reduced prognosis (18, 19). Once cancer cell crosses the intrinsic 
barriers, it will take over the control of additional homeostatic factors (20). Different environmental barriers that 
cancer cells have to cross include physical barrier (basement membrane), chemical barriers (hypoxia, reactive 
oxygen species and low pH), and biological barriers (immune surveillance, regulatory extracellular matrix, 
inhibitory cytokines) (21, 22). Breast cancer cells establish strong interaction with the microenvironment once 
released from primary tumor site and reside in the bone marrow (23). After that, breast cancer cells secrete factors 
that activate NF- κB ligand (RANKL)-dependent and -independent stimulation of osteoclast bone resorption (24). 
Fig. 1.2A shows some pathways in normal bone environment and Fig. 1.2B shows mechanism of metastatic bone 
environment. Breast cancer cells in malignant bone microenvironment secrete growth factors, cytokines and 
parathyroid hormone-related protein (PTHrP) which have negative impact on osteoblast function. In malignant 
bone environment, RANKL is increased and OPG is reduced which leads to more osteoclast formation and bone 
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degradation. A significant reduction occurs in osteoblasts differentiation and no more osteoid is available to 
compensate osteoclastic bone resorption.  
Current therapeutic targets include RANKL, PTHrP and bone hydroxyapatite. Matrix metalloproteinases 
(MMPs), cathepsin K and transforming growth factors (TGF)-β Insulin-like growth factor (IGF), monocyte 
chemotactic protein-1 (MCP-1), Platelet-derived growth factor (PDGF), Vascular endothelial growth factor 
(VEGF) are also under investigation to target bone metastases (25) ( Fig. 1.2B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1.2). The Bone Microenvironment (25). A) Normal bone remodeling processes, B) osteolytic bone 
metastases. 
 
3.2. Bone Pain 
Cancer pain is caused mostly due to metastatic bone disease (26-28). However, it is notable that not all bone 
metastasis lead to pain and pain intensity is not always proportional to size and degree of metastatic lesions in the 
bone. Metastatic bone pain is mostly a neuropathic pain, transmitted by primary efferent nociceptor peripheral 
nerves. These peripheral nerves have many types of receptors for noxious stimuli detection, including acidity, 
lipid metabolites, heat and inflammatory molecules. Persistent acidic and inflammatory environment of metastatic 
lesions cause sustained stimulation, allodynia (central pain sensitization) and hyperalgesia (hypersensitivity to 
pain). Thus, any agent that has potential to antagonize inflammatory mediators can be a potential therapeutic agent 
for managing cancer pain. A single or multiple radiotherapy sessions delivering 8Gy or 20Gy was helpful in 
managing this type of pain (29). Radioisotopes can be administered as a drink, capsule or injection into a vein 
(30). Radioisotopes are easy to administer, less toxic and effective in subclinical metastatic sites but cannot be 
delivered in precise doses (31). Analgesics are recommended for managing metastatic bone pain. Standards of 
care should be accompanied with bone-modifying agents to manage cancer bone pain as they could exert a 
synergistic effect (3).  
 
4.  TREATMENT STRATEGIES 
 
4.1. Treatment for Uncomplicated Bone Metastases 
Treatment options available for treating uncomplicated bone metastasis include bone-targeted agents along with 
radiation therapy. It has been proved that both single and multi-fractionated radiotherapy is equally effective for 
treating uncomplicated bone metastasis (32). 
 A B 
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4.2. Treatment for Complicated Bone Metastases 
Treatment options for complicated bone metastasis mainly include bone surgery and radiotherapy. Zoledronic 
acid, pamidronate or denosumab are recommended to be administered because they have been shown to delay the 
use of analgesics. In a phase III randomized clinical trial, a single dose of 8 Gy radiation was found to be effective 
for palliating spinal cord compression. For the patients who were suffering from bone metastases neuropathic 
pain however, multifractionated treatment (20Gy in 5 fractions) was shown to be more effective than a single 
fractionated treatment (8 Gy in 1 fraction).  
 
4.3. Radiation Therapy 
Mechanism of pain relief following radiation therapy is poorly understood. Many clinical trials with different 
scoring and reporting methods are available but guidelines for irradiation are still unclear because of great 
variation in beneficial results. Three different types of radiation therapy are used including local-field, wide-field 
and radionuclide therapy are shown in Table 1.1 (33).      
 
Table 1.1:  Radiation therapy for bone metastases (33). 
Radiation 
Therapy 
Delivering 
method 
Pain relief rate Examples Indications 
Local-field 
radiation 
therapy 
Conventional 
treatment 
Delivered using 
photons 
80-90%  40-46 Gy/ 20-23 
fractions 
30-36 Gy/10-12 
fractions Gy 
Used for patients with 
localized pain: less than 
four metastatic sites 
without visceral sites (lung, 
liver, central nervous 
system). 
Wide-field 
radiation 
therapy 
Systemic 
radiation therapy 
MeV units (from 
Co 60 to 15 MeV 
linear 
acceleration) 
64-100%  
50-66% of patients 
maintain pain relief 
for remaining life 
 
Upper wide field 
treatment (from 
skull to L2-3) is 6 
Gy 
Lower-wide field 
(from L3-4 to above 
the knees) or mid-
body wide field 
treatment (from L1 
to upper third of the 
femurs) is 8 Gy 
Used for widespread 
symptomatic bone 
metastases or as an 
adjuvant to local-field 
irradiation to reduce 
frequency of re-treatment. 
Radionuclide 
therapy 
Systemic 
radiation therapy 
Radioisotopes 
(high linear 
energy transfer) 
37-91% from 89St* 
58% from 186Re* 
72% of 153Sm* 
  89St 
  186Re 
  153Sm 
  223Ra 
It is used in combination 
with bisphosphonates and 
radiation therapy in the 
treatment of bone 
metastatic disease.  
*St: Strontium, Re: Rhenium, Sm: Samarium, Ra: Radium 
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5.  BONE-TARGETED AGENTS 
 
5.1. Inorganic Pyrophosphates 
Inorganic pyrophosphate analogs, also called bisphosphonates, can exert their role via two mechanisms (34): 
1) Interfering with and hampering the osteoclast survival process. 
2) Stimulating the apoptosis of osteoclasts  
Through these mechanisms, bisphosphonates can regulate bone turnover and reduce tumor-related bone resorption 
(34). Bisphosphonates can be classified into amino-bisphosphonates and non-amino bisphosphonates. Among 
these, amino-bisphosphonates are predominantly utilized in clinical interventions (34, 35).  Ibandronate, 
pamidronate and zoledronic acid (amino-containing) and clondronate (non-amino containing), are 
bisphosphonates (Fig. 1.3) available in clinic to treat bone metastasis from breast cancer (34), prostate cancer 
(36), lung cancer (37) and multiple myeloma (38, 39). Some examples of derivatives in clinical trials are shown 
in Table 1.2 (40). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1.3). Chemical structures of some bisphosphonates 
Zoledroni acid 
Clondronic acid Pamidronic acid 
Ibandronic acid 
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5.2. Denosumab   
Denosumab is a human monoclonal anti-RANKL antibody used for the treatment of osteoporosis, bone 
metastasis, treatment-induced bone loss, and giant cell tumor of bone (41). It inhibits the activation of RANK 
receptors by directly binding to these receptors on the surface of osteoclasts (42).   Inhibition of RANKL-RANK 
receptor interaction by denosumab causes reduction in tumor-induced bone demolition (41, 42). Some clinical 
trials involving denosumab are shown in Table 1.3 (40). 
 
Table 1.3. Clinical Trials for Denosumab (40). 
 
Name  Study 
Phase 
Country Clinical trial 
Gov. Identifier 
Status 
Can denosumab prevent recurrence in the bone 
when given in early stage breast cancer?    
Phase III Argentina 
and 40 other 
countries 
NCT01077154 Ongoing 
Does denosumab reduces the rate of first 
clinical fracture in women with non-metastatic 
breast cancer receiving aromatase inhibitor? 
Phase III Austria, 
Sweden 
NCT00556374 Ongoing 
Study of denosumab with zoledronic acid in 
treatment of bone metastasis in subjects with 
Breast cancer. 
Phase III Argentina 
and 35 other 
countries 
NCT00321464 Completed 
08/03/2017 
Study of denosumab in breast cancer subjects 
with bone metastasis who have not previously 
been treated with bisphosphonates therapy. 
Phase II United 
States 
NCT00091832 Completed 
28/01/2017 
A study to evaluate denosumab in young 
patients with primary breast cancer. 
Phase III Australia, 
Belgium 
NCT01864798 Terminated 
05/09/2017 
 
Study of denosumab as adjuvant treatment for 
women with high risk early breast cancer 
receiving neoadjuvant or adjuvant therapy. 
Phase III Argentina 
and 40 other 
countries 
NCT01077154 Ongoing 
Table 1.2: Clinical Trials for Bisphosphonates (40). 
Goal Study Type Country Clinical trial 
Gov. Identifier 
Status 
Oral bisphosphonates(Alendronate sodium) 
to prevent bone loss in postmenopausal 
women with early breast cancer, receiving 
anastrozole therapy and determine how long 
treatment is needed. 
Phase III Australia NCT00122356 Completed 
13/03/2013 
Identification of Risk Factors` for skeletal 
related events in breast cancer patients 
receiving bisphosphonates for bone 
metastasis. 
Cohort Canada NCT01144481 Completed 
07/01/2015 
Studying long term bone quality in women 
with breast cancer receiving bisphosphonates 
(Clondronate sodium, demeclocycline 
hydrochloride, ibandronate sodium, 
tetracycline hydrochloride, zoledronic acid) 
Observational  United 
States 
NCT00873808 Withdrawn 
10/04/2013 
Safety and efficacy of zoledronic acid when 
added to standard therapies in patients with 
breast cancer and metastatic bone lesions. 
Phase III Germany NCT00372710 Terminated 
23/11/2009 
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5.3. Effectiveness of bisphosphonates in Clinical Trials. 
Bisphosphonates including clodronate, pamidronate, ibandronate and zoledronic acids were widely studied in 
women with breast cancer bone metastasis. These Placebo-controlled trials indicated the effectiveness of 
bisphosphonates for reducing SREs and are summarized in Table 1.4 (43-52). 
 
Table 1.4.  Placebo controlled trials of bisphosphonates (53).  
 
Name Hypercalcemia  Skeletal 
Morbidity 
SREs Pain 
Clodronate 
1600 mg orally daily vs. 
Placebo (43-45) 
Total 
hypercalcemic 
events 
reduced 
Reduced 
Fractures 
Increased time to first 
SREs 
Reduced Pain 
intensity 
Pamidronate 
45 mg i.v. every 3 weeks vs. 
placebo (46) 
   Increased Pain 
relief 
Pamidronate 
90 mg i.v. every 3-4 weeks vs. 
placebo for 2 years  (47) 
  Reduced Proportion of 
patients With SREs 
complications 
 
Pamidronate 
60 mg i.v. every 4 weeks vs. 
placebo (48). 
Increased time to 
hypercalcemic 
events   
 Reduced SREs Increased time 
to progression 
of pain 
Ibandronate 2 mg or 6 mg i.v. 
every 3-4 weeks vs. placebo for 
2 years (49) 
 Reduced 
mean no. of 
bone events 
Increased time to first 
SREs 
 
Ibandronate 50 mg orally daily 
vs. placebo for 96 weeks (50) 
 Reduced 
skeletal 
morbidity 
Decreased risk of skeletal 
related events 
 
Ibandronate 6 mg i.v. every 4 
weeks vs. placebo for 24 
months (51) 
  Reduced Proportion of 
patients With SREs 
complications 
Increased time to first 
SREs 
 
Zoledronic Acid 
4 mg i.v. every 4 weeks vs. 
placebo for 1 year (52) 
  Reduced rate of SREs 
 
Increased time to first 
SREs 
 
 
 
 
5.4. Adverse Effects and Management of Bone-Targeted Therapies   
 
5.4.1. Acute Phase Reaction 
Acute phase reaction (APR) is a systemic host defense response by which the innate immune mechanisms are 
activated due to inflammation, injury or infection. About 10 to 30 % of patients who have been treated with 
zoledronic acid and denosumab were shown to experience APR side effects. This can be observed during first 
three days after treatment. During this process, there is an increase in the number of acute phase proteins (APRs) 
that are involved in homeostasis, causing influenza-like symptoms, chills, fever, lethargy, increased protein 
catabolism, reduced appetite, flushing, bone pain, hypotension, myalgia, and arthralgia (54-57). Laboratory 
analysis shows increased tumor necrosis factor-alpha (TNFα) and interleukin-6, neutrophilia, and leukocytosis. 
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Most of the reactions are spontaneously reversed after 72 hours of first dose application or can also be managed 
with non-steroidal anti-inflammatory drugs and antipyretics (54-56, 58).  
 
5.4.2. Nephrotoxicity 
Bisphosphonates have a renal route of excretion. About 40-70% of administered dose of bisphosphonates is 
excreted through kidneys (57, 59, 60). Unmetabolized bisphosphonates accumulate in tubular cells and can cause 
apoptosis which leads to acute kidney injury. This type of renal injury could be reversible (e.g. zoledronic acid) 
or irreversible (e.g. pamidronate). Denosumab is least likely to cause renal injury and can be used as a choice of 
medication for patients with kidney failure and dependent on dialysis (56, 61, 62). Preventive measures include 
monitoring of phosphate, serum creatinine, calcium levels and avoiding the administration of multiple nephrotoxic 
drugs. Patients with renal impairment should get a reduced dose of zoledronic acid (63). 
 
5.4.3. Hypocalcemia 
Chances of hypocalcemia with bisphosphonates therapy are 3.4-6% and with denosumab treatment is 5.5-13%. 
Clinical manifestation could be, general weakness, lethargy, and fatigue (64-66). Calcium and vitamin D 
supplements are vital, especially for patients having pre-existing vitamin D or renal insufficiency, 
hypomagnesaemia, impaired thyroid and parathyroid activity, geriatric patients or patients having gastric surgery.   
 
5.4.4. Jaw Osteonecrosis 
Jaw osteonecrosis is caused by vascularization defects in the maxilla or the mandibular bone. This may occur 
followed by head and neck radiotherapy, use of bisphosphonates or denosumab (67, 68). During the last decade, 
2% of cases of jaw osteonecrosis have been linked with denosumab therapy and 1.4% with zoledronate therapy. 
Oral health evaluation during bisphosphonates and denosumab therapy is critical to consider. It is essential to 
avoid invasive dental procedures (69, 70). 
 
5.4.5. Rare Side Effects 
Denosumab and bisphosphonates can cause conjunctivitis, scleritis, uveitis (70-75), dermatitis, eczema, rashes 
(76, 77) or rare atypical femur bone fracture (78, 79). 
 
6. NOVEL BONE-TARGETED AGENTS 
Although denosumab and bisphosphonates are potential agents in improving the quality of life of patients with 
breast cancer bone metastasis, they have not been proved to provide progression-free and overall survival 
improvement from the disease. So, research to explore new potential therapeutic agents is going on. Bone 
destruction due to breast cancer is a complicated process and mediators that can serve as the basis for developing 
novel targeted agents are under investigation (80-82).  
 
6.1. Novel targets for osteoclast-mediated bone resorption inhibition   
 
6.1.1. RANKL/RANK 
RANKL/RANK pathway plays a key role in the regulation of bone resorption (41). Osteoblasts have RANKL 
which is a transmembrane surface protein and can be cleaved by proteases into soluble form (83). RANKL (both 
Soluble and membrane-bound forms) can bind to RANK receptors present on the surface of osteoclast precursor. 
After binding with the receptor, they will cause osteoclastogenesis. OPG is a cytokine receptor and a RANKL 
antagonist which is produced by osteoblasts and has the ability to inhibit RANKL/RANK interaction (41). 
Deregulation of RANKL and OPG balance is observed in breast cancer (84). Thus, OPG has potential to reduce 
bone destruction and reduce SREs in breast cancer bone metastasis. This activity is exhibited by enhanced 
osteoclast activity and is confirmed in OPG knockout mice (85-87). 
 
6.1.2. c-Src Kinase Inhibitors 
Cellular Src Kinase (c-Src) is a member of Src family (non-receptor tyrosine kinases), also known as proto-
oncogene c-Src. C-Src phosphorylates specific tyrosine residues in other proteins. Elevated c-Src levels are 
associated with cancer progression (88, 89). c-Src is engaged in performing multiple functions including adhesion, 
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invasion, migration, metastasis, and angiogenesis via chemokine receptor signaling  (CXCL12/CXCR4/Akt) 
pathway or by inhibiting the functions of apoptosis - inducing ligand pathway (90). Enhanced expression and 
increased activity of c-Src has been investigated in a variety of cancers. Inhibitors of c-Src kinases have been 
proven to play a pivotal role in tumor cell invasion and proliferation. Selective tyrosine kinase inhibitors (TKIs) 
cause inhibition of c-Src kinases by blocking osteoclast differentiation (91, 92). Some preclinical investigations 
reported that dasatinib, bosutinib, and saracatinib have inhibited osteoclast differentiation (90, 93, 94). Dasatinib 
monotherapy has proven efficacious in advanced breast cancer bone metastasis patients (95, 96). Related clinical 
trials are shown (Table 1.5). 
 
Table 1.5.  Investigated targets for the treatment of bone metastasis (40). 
 Target Compound Phase Country Clinical trial 
Gov. Identifier 
Status 
Cathepsin K odanacatib Phase 
III 
United 
States 
NCT00691899 Withdrawn 
12/08/2016 
C-Src dasatinb Phase 
II 
United 
States 
NCT00410813 Completed 
02/072017 
Ανβ3 integrin etaracizumab  None      
TGFβ fresolimumab  None    
 trabedersen None    
 galunisertib None    
CXCL12/CXCR4 plerixafor None    
 LY2510924 None    
 
 
6.1.3. Cathepsin K (CTSK) 
Cysteine cathepsins are among hydrolytic enzymes and members of the family of papain-like cysteine proteases 
in lysosome. A cysteine lysosomal protease, called cathepsin K or CTSK is primarily present in osteoclasts. It 
induces degradation of bone collagen and ultimately causes bone resorption (84, 97). A preclinical investigation 
done in animal models of breast cancer bone metastasis showed cathepsin K inhibitors are effective in preventing 
bone destruction. Furthermore,  cathepsin K antagonist can play their role not only in bone resorption inhibition 
but also in stimulation of bone formation (98). Cathepsin K may directly act on cancer cells. Odanactinib (a 
cathepsin K inhibitor) has been proved to successfully reduce the level of bone resorption marker called urinary 
N-telopeptide of type-I collagen. However, there may be some disadvantages associated with cathepsin K 
inhibitors. For example, balicatib (AAE-581, Novartis) is a nitrogen-containing cathepsin K has the ability to 
accumulate in lysosomes. Due to this accumulation, activities of other lysosomal cysteine cathepsins are inhibited 
which may lead to severe adverse effects like stroke and skin reactions. For example, morphea-like skin reactions 
are noticed in a phase II clinical trial in which patients received balicatib therapy for 12 months. As a result, 
balicatib was withdrawn from clinical trials (97, 99). This adverse effect is not shown by odanacatib (MK-0822, 
Merck), which is under clinical trial investigation for osteoporosis treatment. Odanacatib has successfully reduced 
bone resorption markers in a phase-II trial in women having breast cancer bone metastasis after four weeks of 
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therapy (100).  But odanacatib was withdrawn from the regulatory approval process due to increased risk of stroke 
(101). 
 
6.1.4. Integrins 
Integrins belong to a heterodimeric transmembrane glycoprotein family that mediates adhesion to extracellular 
matrix proteins and immunoglobulins. So far, 24 heterodimers have been developed by incorporating 18α and 8β 
subunits. Many types of integrins have an association with bone metastasis but ανβ3 performs a more crucial role 
in osteoclast function and bone metastasis (102). According to a preclinical study, some peptidic (e.g. S247, 
cilengitide, ATN-161) and non-peptidic (e.g. PSK1404) compounds that target ανβ3 could inhibit osteolysis and 
tumor growth in bone metastasis animal models (103, 104). These ανβ3 inhibitors, not only antagonized the 
osteoclast-mediated bone resorption but PSK1404 also prevented bone colonization by cancer cells expressing 
ανβ3 integrins at the dosage regimen that does not block bone resorption (103). GLPG0187, ATN-161, IMGN388, 
cilengitide are different ανβ3 antagonists which are in clinical trials for breast cancer bone metastasis 
(105).Clinical trial investigations revealed that L-000845704 (a non-peptide antagonist developed by Merck) 
could, inhibit bone resorption in osteoporosis. Investigations are underway to study its applications in oncology 
as well (105).  
 
6.1.5. Proteasome 
Proteasome is an extra-lysosomal proteolytic enzyme complex. The ubiquitin-proteasome system is involved in 
degrading intracellular proteins. This system involves the tagging of many intracellular proteins with ubiquitin 
(which is a small regulatory protein) and then these intracellular proteins are recognized by 26S proteasome 
complex, resulting in the degradation of these proteins into small peptides. Many proteasome inhibitors (PIs) are 
under clinical investigation. Preclinical data suggested that PIs exert their effect on three kinds of cells. First, by 
inhibition of osteoclast differentiation and their function (106). Second, they enhance bone formation through 
stimulating osteoblasts differentiation, up-regulating bone morphogenetic protein 2 (BMP-2) and inhibiting runt-
related transcription factor (RUNX2) (107). Finally, PIs block cell proliferation and activate apoptosis in many 
cancer cells (108, 109) and induce osteolysis in breast and prostate cancer bone metastasis in animal models(110, 
111). However, clinical trials did not show the expected results. 
 
6.1.6. Hedgehog 
Cancer progression involves the activation of Hedgehog (Hh) signaling pathway (112) which is also important in 
the regulation of cancer stem cells. Hh ligand (Desert, Indian and Sonic Hh) bind to transmembrane protein 
receptors (Patched receptors). Hh Inhibitors exert direct cytotoxic effects on cancer cells. In preclinical animal 
models, Hh inhibitors blocked osteoclastogenesis and bone metastasis. A phase II clinical trial was designed to 
investigate the effect of selective SMO (it is a smoothened protein encoded by SMO gene) antagonist (sonidegib) 
in early stage breast cancer (NCT01757327), but it was withdrawn before enrolment. 
 
6.2. Novel targets for restoration of osteoblast functions 
 
6.2.1. Dickkopf-1 (DKK-1) 
Wnt signaling pathways are protein signal transduction pathways that pass signals into the cell through cell surface 
receptors. DKK-1 is a glycoprotein with a significant role in amphibian’s head formation via antagonizing the 
Wnt signaling pathway. Osteoblastogenesis process involves Wnt signaling pathway. Wnt proteins in association 
with low density lipoprotein receptor-related proteins 5 and 6 (LRP5/6), bind Frizzled receptors (G Protein-
coupled receptors) and initiates signaling via β-catenin. This process activates different genes involved in 
osteoblastogenesis (113). DKK-1 binds to LRP5/6 and blocks its binding with Wnt-1, causing breakdown of β-
catenin and inhibit osteoblast differentiation. DKK-1 was shown to be elevated in serum and bone marrow of 
patients with multiple myeloma (114). Neutralizing antibodies that block DKK-1 cause reduction in osteolysis, 
skeletal tumor growth in addition to an increase in the osteoblast number and osteocalcin level in the serum (115, 
116). There are some preclinical and clinical evidence that breast cancer cells that metastasize to bone secrete 
DKK-1 (117). A Phase I clinical trial investigates a combination of DKK1-neutralizing antibody, BHQ880 and 
zoledronate in myeloma patients(117). 
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6.2.2. Sclerostin 
Sclerostin is a secreted glycoprotein that is encoded by SOST gene. It is produced by osteocytes. Sclerostin 
promotes migration, invasion of cancer cells and osteolysis and has anti-anabolic effect on bone formation. 
Sclerostin binding to LRP5 receptors can be blocked by antibodies that neutralize sclerostin (118). Sclerostin 
neutralizing antibody is used to treat osteoporosis e.g. romosozumab (119). However, no clinical trial is available 
to study the effects of sclerostin-blockers on metastatic bone disease. 
 
6.2.3. Activin A 
Activin A is widely distributed in all human tissues and belongs to TGF-β family of growth factors. Serine and 
threonine kinase transmembrane receptors mediate the effects of activin A. Activin A activates ActR1B or ALK-
4 type 1 receptors that leads to the phosphorylation of receptor-regulated Smad proteins (RSmad4), Smad2, 
Smad3 and Smad4. Activin A gets entered in the nucleus that results in gene transcription regulation in bone cells. 
Activin A activates bone degradation, triggers osteoclast differentiation and inhibits osteoblast differentiation 
(120). Higher serum levels of Activin-A are found in breast cancer patients with bone metastasis as compared to 
the patients without bone metastasis (121). Therefore, this cytokine can be regarded as a potential target for more 
specific treatment measures for skeletal metastasis. In an in vivo humanized multiple myeloma induced bone 
disease model, Activin A targeting by a soluble decoy receptor, reversed osteoblast inhibition and inhibited tumor 
growth (122). RAP-011 is an activin type IIA receptor fused to a murine IgG-Fc fragment can restore bone mass 
(123). Recently, different groups have shown the combined effect of RAP-011 with Act RIIA receptors to serve 
as potential therapeutic targets in treatment of skeletal metastasis. RAP-011 can be measured as biochemical 
marker of bone metastatic disease (121). Sotatercept (ACE-011), a recombinant activin receptor type IIA and 
human globulin G (IgG), binds to activin A receptors. Sotatercept is potentially important for preventing bone 
loss and deposition of new bone in myeloma patients with osteolytic lesions (124). Sotatercept treatment 
demonstrated clinically significant decrease in bone pain, increase in the bone formation biomarkers, antitumor 
activity and increase in hemoglobin levels (125, 126).  
 
6.2.4. Endothelin-1 
Endothelins are peptides that constrict blood vessels. They produce their effect by binding to their receptors, ETA 
and ETB1, ETB2 and ETC receptors. Breast cancer cells produce endothelin-1 (ET-1) that activates mitogenesis in 
osteoblasts, resulting a reduction in osteoclast activity (127). ETA antagonist ABT-627 (atrasentan) could inhibit 
osteoblastic breast cancer bone metastasis (128). Bosentan is a dual endothelin receptor antagonist (ETA and ETB 
receptor) approved to be used in treatment of pulmonary artery hypertension. This mixed inhibitor was shown to 
block breast cancer bone metastasis in vivo (129).  
 
6.3. Novel Targets for Bone-Derived Growth Factors 
 
6.3.1. Transforming growth factor-Beta (TGF-β) Signaling 
TGF-β is a multifunctional cytokine of transforming growth factor superfamily, having four different isoforms 
(TGF-β1, TGF-β2, TGF-β3 and TGF-β4). 
TGF-β binds to TGF-β type I receptor (ALK5) and TGF-β type II receptors (TβRII) which are serine/threonine 
heterodimeric kinases. It phosphorylates Smad2 and Smad3 which are TGF-β specific mediators. This 
Phosphorylated complex then binds to Smad4 and translocates to the nucleus and regulates TGF-β genes. TGF-β 
in turn regulates the growth of many factors like IL-6, IL-8, IL-11, integrin ανβ3, MMP-1 and CXCR-4 which 
play a key role in bone metastasis (130).   
Hence inhibition of the TGF-β signaling can be considered as a potential target to reduce bone metastasis. Many 
strategies have been developed to block TGF-β signaling including TβRI inhibitors, dominant negative TβRII, 
neutralizing TGF-β antibodies and antisense oligonucleotides. These have been investigated to inhibit bone 
metastasis to breast cancer in preclinical trials. Although the effects of these TGF-β inhibitors have been 
investigated in different types of cancers, no clinical trials have been performed to explore their effect in breast 
cancer bone metastasis (130, 131).   
Epithelial-to-mesenchymal transition (EMT) process has been found to play a role in cancer and metastasis 
progression. In this process, epithelial cells gain migratory and invasive properties and become mesenchymal 
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stem cells and initiate metastasis. TGF-β signaling through Smad pathway serves as an effector of this process 
(132). Exogenous Bone morphogenetic protein-7 (BMP-7) inhibits TGF-β signaling which antagonizes EMT 
signaling in prostate and breast cancer bone metastasis model in animals (133, 134). Another animal study 
revealed the role of TGF-β signaling in the regulation of the Jagged1-Notch pathway. Jagged1 is a cell surface 
protein that regulates Notch signaling pathway. Up-regulation of JAG 1 has been found to be associated with poor 
breast cancer survival rates. MRK-003, a γ-secretory inhibitor, has shown to inhibit Jagged1-Notch signaling 
pathway and hence cause a reduction in bone metastasis to breast cancer (135). These findings revealed that a 
strategy against breast cancer bone metastasis can be developed based on TGF- β-dependent EMT signaling, γ-
secretase or BMP-7 inhibitors. 
 
6.3.2. Insulin-like Growth Factors (IGFs)   
Insulin-like growth factors (IGF-I and IGF-II) exist abundantly in bone and have been involved in spreading, 
development and aggressiveness of many different cancers. IGFs exert their action by binding to IGF type I 
receptors (IGF-IR). IGFs activate IGF-IR/Akt/NF-kB pathway, stimulates proliferation and increases bone tumor 
burden (136). An IGF-IR inhibitor e.g, PQIP (Chemical formula C3OH31N7) reduced the osteolytic lesion size 
in breast cancer bone metastases (137).  
 
6.4. Novel Agents Targeting Bone Environment 
 
6.4.1. Chemokine Receptor Signaling (CXCL-12/CXCR-4) 
Almost all types of cells secrete chemokines.  Most of the chemokines are involved in adaptive and innate immune 
systems, while a few of chemokines such as CXCL-12 that are produced by the osteoblasts, play a pivotal role in 
the regulation of cellular trafficking. It is proved that chemokines play a vital role in cancer metastasis (138). 
Chemokine receptors like, CXCR3, CCR4, CXCR4, CCR5 and CCR7 and especially CXCR, are found to be 
involved in the metastasis regulation process. CXCR4 is found to play a fundamental role in organ-specific breast 
cancer metastasis, including liver, lung and bone metastasis. In these organs CXCL-12 (CXCR4 ligand) is 
produced in high quantity (138).  
The proposed mechanism is that after CXCL-12 binds to CXCR4 and activates the non-receptor Src, tyrosine 
kinase, AKT pathway is activated in bone marrow breast cancer cells (139). Consequently, the CXCL-12/CXCR-
4 pathway can serve as a targeted therapy to treat bone metastasis. Synthetic peptide antagonist like CTCE-9908 
and antibodies could block this CXCL-12/CXCR-4 pathway and reduce bone and lung metastases caused by 
breast cancer cells in preclinical experiments (140, 141).   
 
6.4.2. Cadherin-11 
Osteoblasts and bone marrow stromal cells express cadherin-11, which is a member of type 2 cadherin family. In 
one animal study it was demonstrated that the overexpression of cadherin-11 in breast cancer cells was associated 
with metastasis to bone but not to the lungs. This finding suggested that cadherin-11 can be used as a specific and 
novel target for treating bone metastasis. Yet, no agent has reached clinical trial (136). 
 
6.4.3. Targeting Runx2 
The bone transcription factor Runx2 that is a member of Runt-Related Transcription factor (Runx) family has 
crucial role in bone development by controlling osteoblasts and osteoclast processes (142, 143).  It has been 
proved that Runx2 facilitate the interaction between cancer cells and the microenvironment of bone. Runx2 
suppresses the ubiquitination of oculo-dento-digital dysplasia-hypoxia inducing factor (ODDD) HIF-1α by 
directly binding to ODDD-HIF-1α. Vascular angiogenesis during endrochondral bone formation is regulated by 
HIF-1α and vascular endothelial growth factor (VEGF). Runx2 has been identified to be involved in tumor 
invasion by regulating matrix metallopeptidase 9 (MMP9) (144). It has also been proved to play a crucial role in 
osteoclasts activation by gene regulation for OPN, M-CSF and PTHrP. Runx2 indirectly blocks Wnt signaling 
pathway and promotes activation of osteoclasts (144). 
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6.4.4. Targeting microRNAs (miRNAs) 
MicroRNAs (miRNAs) belong to 21-23nucleotide- noncoding, long RNAs which are transcribed by RNA 
polymerase types II and III. Generally, miRNA cause either mRNA degradation or translational silencing by 
binding to their complementary site at the 3-untranslated region (145). It is evident that normal and cancer cells 
have different expressions for miRNAs. They can either enhance or inhibit the development and progression of 
the tumor. Many types of miRNAs have been found to be involved in regulation of bone metastasis (146). Thus, 
miRNAs involved in bone metastasis development can serve as a target for treating breast cancer bone metastasis. 
Very few miRNAs, e.g. miR-141 and miR-219, are found to inhibit osteoclast activity and osteolytic activity in 
breast cancer bone metastasis. miR-203 and miR-219 also have reducing effects on breast cancer bone metastasis 
(147). Several miRNAs associated with cancer have been discovered in humans, including miR-10b, miR-16-2, 
miR26a1, miR26-a2, miR-126, miR-17-92, miR-15b (148). 
Several miRNAs, either directly or indirectly, regulate Runx2 in breast cancer progression. miRNAs are associate 
with bone metastasis initiation (let-7g, miR-146a, miR-335, osteolytic activity (miR-133a, miR-190). Further 
investigation is required to explore the regulatory role of Runx2 via miRNA and its potentials as a novel target 
for bone metastases (144). 
 
6.5. Targeting Cancer Stem Cells 
Stem-like cells (CSCs) are tumorigenic cells and may generate tumors through the stem cell renewal and 
differentiation (149, 150). The bone marrow biopsy sample from cancer patients showed that majority of early 
metastatic cells have CSC markers (150, 151). In a recent pre-clinical study, CD44-positive CSC-like cells were 
shown to have an increased capacity to metastasize to bone (152). Cancer stem cells markers include CD44 
(breast, prostate and liver cancers), E-Cadherin (prostate, breast and brain cancers), CD166 (cellular proliferation), 
CD13 (liver cancer), CD90 (liver, breast and lungs cancers), CD105 (renal, breast and liver cancers (153, 
154))The CSC biology is yet to be fully understood. CSCs and their niches could be considered as targets for 
preventing and treating breast cancer bone metastasis (154).  
 
6.6. FDA approved Drugs for Cancer Treatment available on the market. 
Some of the FDA approved breast cancer drugs are given in Table 1.6.  
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Table 1.6: Some FDA approved drugs for breast cancer available on the  market (19) 
 
Brand Name Generic Name Manufacturer Drug 
Type 
Indication Approval Date 
Perjeta Pertuzumab Genentech Monoclonal 
Antibody 
First line treatment of 
HER2+ metastatic breast 
cancer 
June 2012 
Halaven Eribulin 
mesylate 
Eisai Macrocyclic 
Ketone 
Analogue 
Metastatic breast cancer November 
2010 
Xgeva Denosumab Amgen Human 
Monoclonal 
Antibody 
Preventing skeletal-
related events in patients 
with bone metastasis 
from solid tumors 
November 
2010 
Evista Raloxifene 
hydrochloride 
Eli Lilly Estrogen 
receptor 
modulator 
Prevention/Treatment of 
osteoporosis and 
reduction of breast cancer 
risk in postmenopausal 
women 
September 
2007 
Ixempra ixabepilone Bristol-Myers 
Squibb 
Epothilone B 
Analog 
 
Breast Cancer October 2007 
Tykerb lapatinib GlaxosmithKline Dual Tyrosine 
Kinase Inhibitor 
Breast cancer March 2007 
Herceptin Trastuzumab Genentech Monoclonal 
Antibody 
Metastatic breast cancer October 1998 
Nolvadex Tamoxifen 
citrate 
AstraZeneca Selective 
estrogen 
receptor 
modulator 
Breast Cancer October 1998 
Xeloda Capecitabine Roche Antimetabolite Advanced breast cancer 
tumors 
April 1998 
Quadramet Samarium Sm 
153 
Lexidronam 
Injection 
Dupont Merck 
Pharmaceutical 
Company 
Chelated 
complex 
Pain associated with bone 
cancer 
March 1997 
Aredia Pamidronate 
disodium for 
injection 
Chiron Nitrogen 
containing 
Bisphosphonate
s 
Osteolytic bone 
metastasis of breast 
cancer 
August 1996 
Arimidex Anastrozole Astrazeneca Aromatase 
Inhibitor 
Advanced breast cancer 
in postmenopausal 
women 
January 1996 
Taxotere Docetaxel Rhone Poulenc 
Rorer 
 
Microtubule 
Inhibitor 
Locally advanced or 
metastatic breast cancer 
May 1996 
28 
 
 
7. CONCLUSION  
Bone metastasis significantly affects the quality of life of patients with breast cancer and new targeted strategies 
are in urgent demand to prevent and palliate skeletal events. Currently available clinical treatments can often 
shrink or slow the growth of bone metastases. However, these treatments are not able to eradicate bone metastatic 
foci. Bone metastasis progresses over time and leads to SREs, substantial morbidity and mortality and there is 
insufficient evidence available to demonstrate which bone modifying agent is the preferred choice. Advances in 
the discovery of different novel targets described in this review, not only provides insights into making a better 
use of the currently available agents but also the development of new targeted therapeutic interventions. These 
novel targets can also be used in combination with the treatment options available in clinic to effectively inhibit 
the development of bone metastasis in women with breast cancer. More in-depth preclinical and clinical 
investigations are required to optimize the current treatment strategies by elucidating the interactions between 
tumor cells and bone microenvironment to reach maximum effectiveness. Further investigations are warranted to 
discover new agents that can prevent bone metastasis in breast cancer patients to avoid the associated morbidity 
and mortality due to the bone metastasis. 
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Abstract 
The most common cancer among women is breast cancer. According to an estimation by breast cancer 
network Australia, 18,087 women will be diagnosed with breast cancer in 2018. About 70% of the 
metastatic breast cancer patients develop bone metastasis. In pre-clinical investigations, curcumin was 
reported to be non-toxic even at doses of 12 g per day. However, with this high dose of curcumin, 
plasma concentration of curcumin is only 50 nM. The reason for this low plasma concentration of 
curcumin is low water solubility and instability. We have previously developed a new nanoformulation 
of curcumin (Cur-NP) with enhanced physicochemical properties as well as improved antitumor 
activity in breast cancer cell lines. Furthermore, we have formulated alendronate-conjugated curcumin 
nanoparticles (Aln-Cur-NPs) for the targeted delivery of the drug payload (curcumin in this project) to 
the bone. This project aims to investigate the in vitro biological effects of Aln-Cur-NPs that are 
developed to prevent breast cancer bone metastasis.  The loading capacity and particle size of the new 
batch fabricated for this study was determined and was shown to be consistent with previous batches 
of Aln-Cur-NPs and Cur-NPs. The loading capacity was found to be 4% and 5.7%, and the size was 28 
nm and 23 nm for Aln-Cur-NP and Cur-NP, respectively. In vitro anti-tumor activity of the curcumin 
nanoparticles with and without alendronate conjugation, was evaluated in three different breast cancer 
cell lines and reported as IC50 values equivalent to the concentration of curcumin. A significantly higher 
antitumor activity was observed for Aln-Cur-NP compared to Cur-NP with IC50 values of 13.9, 22.2 
and 7.7 µg/mL for MCF-7, MDA-MB-231 and SK-BR-3, respectively. This study showed the enhanced 
anticancer activity of curcumin nanoparticles conjugated with alendronate compared to Cur-NPs, which 
strongly supports the synergistic effect of curcumin/bisphosphonates combination considering the 
similar amount of uptaken curcumin by the cancer cells for both nanoparticle formulations. The impact 
of nanoparticles on the viability of MDA-MB-231 cells was also investigated using recording 
time lapse image technology by IncuCyte® Zoom over two days. It was demonstrated that the 
uptake of raw curcumin was much less, and it precipitated outside the cells while curcumin 
encapsulated in nanoparticles was effectively uptaken by the cancer cells. In the same 
experiment, we observed that Aln-Cur-NPs reduced the viability of the cells more effectively 
than Cur-NPs and raw curcumin. 
The uptake of Aln-Cur-NPs and Cur-NPs in nucleus and cytoplasm in MDA-MB-231after 24 hours of 
treatment was revealed by Confocal Scanning Laser Microscopy. The qualitative analysis of confocal 
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images showed higher uptake for Aln-Cur-NPs compared to raw curcumin (p ˂0.0001) and no uptake 
for the untreated (PBS) control. Parathyroid Hormone Related Protein (PTHrP) release is increased by 
cancer cells in bone microenvironment and promotes osteoclastic activity and contribute to osteolytic 
bone metastases. The effect of our nanoparticles on the release of PTHrP was determined by PTHrP 
ELISA assay for quantitative measurement of human PTHrP concentration released by MDA-MB-231 
cells. MDA-MB-231 cells were treated with alendronate-modified and non-modified curcumin 
nanoparticles. Results showed a reduction in the release of PTHrP by MDA-MB-231 cell lines by both 
curcumin nanoparticles compared to the negative control (PBS-treated). Cur-NP and Aln-Cur-NPs 
twice higher activity on the reduction in the release of PTHrP compared to raw curcumin. These results 
suggested the possibility of reducing osteolytic activity of the cancer cells in bone metastasis. These 
preliminary data suggest Aln-Cur-NPs can offer promises in preventing and treating breast cancer bone 
metastases.   
 
1. Introduction 
The most commonly diagnosed cancer in women is breast cancer (1). About 70% of the metastatic 
breast cancer patients develop bone metastasis (2). Median survival for patients with breast cancer bone 
metastasis is 19-25 months (3). Bone metastasis is a major cause of morbidity as it leads to impaired 
mobility, pathologic fractures, severe pain, bone marrow aplasia, spinal cord compression and 
hypercalcaemia (2). The biggest problem encountered in treating cancer is the inability to deliver 
effective drug to the cancer cells without affecting the normal cells (4). The new treatment strategy for 
treating cancer requires targeted delivery of drug to only cancer cells with more advantages and less 
side effects (5). 
Tumor cells interact with the microenvironment of specific organs to produce metastatic lesio ns 
(6). According to Stephen Paget’s ‘seed and soil’ hypothesis, tumor cells act as ‘seeds’ and have 
affinity for particular ‘soil’, that is, the ‘organ’ (7, 8). Once cancer cells target a specific organ, 
they take control of the whole environment (Fig. 2.1). Cancer cells during epithelial-to-
mesenchymal transition (EMT), loose epithelial polarization and cell surface intercellular 
adhesion proteins in order to exhibit mesenchymal properties (9). Subsequently, tumor cells 
release proteolytic enzymes to dissolve extracellular matrix of tumor stroma (10).Then, cancer 
cells can invade local tissue, migrate to the surrounding cells (11, 12) and enter the systemic 
circulation, known as circulating-tumor cells (CTC) (13-15). Furthermore, tumor cells develop 
certain mechanisms to escape from immune cells through mechanisms that involve up-regulation 
of CD47 proteins (16, 17). Cancer cells develop different signaling pathways to promote CTCs 
to develop metastatic lesions. One of these signaling pathways is the development of chemokine 
receptor (CXCL12-CXCR4) signaling for cancer cell adhesion and survival (18-23). Different 
studies demonstrated the expression of non-receptor cytoplasmic tyrosine kinase (Src) in the bone 
marrow through stimulation of CXCL12-CXCR4 receptors and by increased resistance to tumor 
necrosis factor (TNF) related apoptosis-inducing ligand (TRAIL) in bone marrow 
microenvironment (24).  
After invasion to bone, cancer cells become either osteolytic (promote bone break down) or 
osteoblastic (promote bone formation) (25). Breast cancer normally cause osteolytic lesions and 
have the highest rates of fracture (26).  
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Recently, it is demonstrated that T cells and B cells immune cells can also produce receptor 
activator of nuclear factor kappa-B ligand (RANKL binds RANK on osteoclasts), affect 
osteoclastogenesis and  proliferate bone metastatic environment (27). Adipocytes support cancer 
cells to survive as an energy source (28, 29). Tumor cells secrete osteolytic factors such as 
vascular endothelial growth factor receptor (VEGF), PTHrP, Interleukin-6 (IL-6), IL-8 and IL-
11. These factors stimulate osteoclastic bone resorption either directly stimulating osteoclast or 
indirectly by increasing the RANKL/OPG ratio. Osteoprotegerin (OPG) is a decoy receptor to 
RANKL produced by osteoblasts. Tumor cells secrete various growth factors like platelet -derived 
growth factors (PDGFs), bone morphogenetic proteins (BMPs), transforming growth factor 
(TGF-β) and fibroblasts growth factors (FGFs) help in osteoblasts differentiation (30, 31). 
Osteoblasts form osteocytes and get captured in the bone. Osteocytes regulate osteoclast 
development through macrophage colony stimulating factor (M-CSF), receptor activator of 
nuclear factor kappa-B ligand (RANKL) and osteoprotegerin (OPG). They also inhibit 
osteoblasts differentiation (Fig. 2.2) (27, 32).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2. 2): Different mediators released during bone metastases 
Fig. (2.1):  Effect of cancer cells on bone microenvironment 
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Osteoblasts also secrete TGF-β and IGFs into mineralized bone matrix. Hydroxyapatite (bone 
mineral structure) liberates BMPs, TGF-β, IGFs and FGFs. These factors further worsen the 
metastatic lesions (33). PTHrP predominantly increase osteolytic lesions (34). 
 
Treatment strategy for bone metastases revolves around three main principles [33]. These 
principles include; 1 treatment of cancer cells to prevent their invasion to the bone; 2) targeting 
bone microenvironment to inhibit the vicious cycle phenomenon caused by bone resorption as a 
consequence of bone metastatic cancer and; 3) use of palliative therapies to improve quality of 
life of cancer patients (35). Bone metastases are incurable and associated with significant 
morbidity due to so-called skeletal-related events (SREs) defined as pathological fractures, 
pain, spinal cord compression, etc. and reduced quality of life in women with advanced breast 
cancer (36, 37). Despite the use of these increasingly potent bone-targeted agents, progress in 
terms of absolute reductions in the occurrence of SREs is modest, more effective therapies are 
clearly needed. 
Curcumin, the active ingredient of turmeric (Curcuma longa) possesses anti-oxidant and anti-metastatic 
properties (38-42). It is non-toxic even at high doses (8–12 g/day) (42-46). However, several 
properties limit its therapeutic potential such as its low metabolic stability and poor water 
solubility (i.e, 0.001 mg/mL) (43-46). Different strategies can be used to improve the solubility, 
stability and accumulation of drug molecules in cancerous cells. Use of nanodrug delivery systems has 
been shown to be a promising strategy to address these issues (47-51). Moreover, surfactant used in 
such micellar preparations (the commonly used ones being  polyethylene glycol (PEG), pluronic 
F-127 (52) and chitosan (50)) prevent protein adsorption, reducing the chances of 
reticuloendothelial system (RES) clearance and improving  the enhanced permeability and 
retention (EPR) effect in tumors (49).  
We have previously developed a nanoparticle drug delivery system which could improve the 
solubility issue associated with the use of curcumin (53). In the current project, we used the 
targeting and anti-bone-resorptive potential of bisphosphonates (54) together with anticancer 
and anti-bone-resorptive effects of curcumin (55, 56) to prevent and treat breast cancer bone 
metastasis.  
To target curcumin to the bone, we conjugated the nanoparticles with alendronate. Alendronate 
will increase the accumulation of the nanoparticles to the bone. Alendronate is a   
bisphosphonates drug used for treating osteoporosis and other bone diseases and it inhibits bone 
demineralization (57). Alendronate is one of the most extensively studied bisphosphonates in 
treating osteoporosis. Bisphosphonates exert their effect after binding to the bone mineral due to 
their high affinity to bone calcium, appearing at a high concentration in resorption lacunae  
(cavities formed by osteoclasts for bone resorption) (Fig. 2.3). After binding, bisphosphonates 
are internalized by the osteoclasts, leading to a disruption in bone resorption processes (3, 58). 
Several studies suggest that bisphosphonates cause apoptosis of osteoclasts and thus may have 
direct apoptotic effect on tumor cells (3, 58). In cancer treatment, bisphosphonates are considered 
as standard treatment for tumor-induced hypercalcemia and bone metastasis (59). They are also 
clinically effective in osteoporosis, osteogenesis imperfecta (brittle bone disease) and Paget’s 
disease (abnormal enlargement and weakening of bone disease) (60-62). 
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In our current study, we have studied the biological characteristics of alendronate -modified 
curcumin nanomicelles in breast cancer cells. In this current study, we have performed various 
in-vitro biological evaluations. 
 
Fig. (2.3): Targeted drug delivery system to the bone. 
2. Materials and Methods:  
2.1. General 
Compounds: Curcumin (purity > 80%) and pluronic acid® F-127 were purchased from Sigma-
Aldrich Australia. Alendronate sodium trihydrate was obtained from Alcon-Biosciences 
PVT.LTD. India.  
Cancer Cells: Human breast cancer cells MDA-MB-231, MCF-7 and SK-BR-3 were gifts from 
Professor Robert Baxter’s laboratory which were purchased from ATCC. MDA -MB-231cells 
were cultured in 5% Fetal Bovine Serum (FBS) Roswell Park Memorial Institute (RPMI) 
medium. MCF-7 and SK-BR-3 cells were cultured in 10% Fetal Bovine Serum (FBS) Roswell 
Park Memorial Institute (RPMI) medium. Breast cancer cells were maintained at 37º C 
humidified 5 % CO2 and 95 % O2 atmosphere.  
Instruments: High performance liquid chromatography (HPLC), Leica Spe-ll Confocal Laser 
Scanning Microscopy (CLSM), IncuCyte Zoom, IncuCyte S3, Human PTHLH® ELISA Kit was kindly 
supplied by Wuhan Fine Biological Technology Co., LTD. Flat-bottomed well plates and pipettes were 
supplied by Corning. Australia.  
Solvents: HPLC grade dichloromethane (DCM), HPLC grade acetonitrile (MeCN), HPLC grade 
methanol (MeOH), DMSO were purchased from sigma. ProLong Gold Antifade mounting media, 
Hoechst labelling solution were purchased from Solarbio. Australia., Triton-X 100, 4% formaldehyde, 
Phosphate Buffere saline (PBS), FBS, MTT reagent were obtained from sigma. TGF-β was supplied by 
Prospec-Tany Technogene.LTD. Purified deionized water was prepared using the Milli-Q system.  
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2.2. Preparation of Nanoparticles 
Curcumin nanoparticles and alendronate nanoparticles were prepared using anti -solvent method 
according to our previous studies which has been submitted for publication. Poloxomer F-127 
(10 g) was converted to F-127-COOH by dissolving in DCM (45 mL) by succinic 
anhydride reaction. F-127-COOH wasbe purified by precipitation with ice cold water. 
Sodium alendronate (500 mg) was dissolved in water. It was added to the mixture of F-
127-COOH (2 g) and Milli-Q water (70mL). Amino terminal of alendronate was bind to 
the carboxyl group of modified F-127. After dialysis for 24 hours, Aln-Cur-NP was 
freeze-dried and characterization was done by NMR (52).  
 Characterization of Nanoparticles: 
2.2.1. Determination of Loading Capacity (LC%) & Drug Encapsulation Efficiency 
High performance liquid chromatography (HPLC) was used to determine drug loading (LC%) of the 
new prepared batches of nanoparticles. About 5 mg of curcumin-loaded nanoparticles were dissolved 
in water. Unloaded curcumin was removed by centrifugation at 10,000 RPM for 10 min. 
Supernatant was collected, lyophilized and dissolved in 20 mL of dichloromethane (DCM) to disrupt 
micelles. Extra DCM was removed by evaporation, and dry mass (entrapped curcumin) was collected. 
This dry mass was dissolved in HPLC solvent (5 ml) to achieve a 1 mg/mL solution (As we have used 
curcumin loaded nanoparticles).. Briefly, 50 µL of sample was injected into the HPLC system using 
Solvent A (40% methanol + 10% water) and Solvent B (50% acetonitrile) as the mobile phase at a flow 
rate of 1 mL/min with an isocratic pump at 25 0C and C18 column (Nova-Pak, 150 x 4.6 mm, 4µm). 
The following equation was used to calculate drug loading and a standard curve was plotted for raw 
curcumin (Figure 4).                                            
  (%) LC = [Entrapped Drug / Nanoparticles weight] x 100 
Drug encapsulation efficiency (DEE) was determined using following equation 
DEE = (Experimental drug loading / Theoretical drug loading (TDL)) x 100 
2.3.  In vitro biological evaluations 
2.3.1.  In vitro anticancer activities of the nanoparticles (MTT Viability Studies) 
The in vitro anti-cancer properties of nanoparticles were investigated against three breast cancer cell 
lines with different receptor expression characteristics including MDA-MB-231, MCF-7 and SK-BR-3 
using MTT cell viability assay. The cells were passaged and plated (at 90 μL/well) in flat-bottomed 96-
well plates at 2 × 105 cells/mL. Drug solutions were prepared by dissolving Aln-Cur-NPs and Cur-NPs 
and void nanoparticles in PBS while raw curcumin solution was prepared by dissolving it in 0.5% 
DMSO at curcumin equivalent concentrations of 0.1, 1, 10, 25, 50 or 100 µM (n = 3 in triplicate). 
Treated cells were incubated for 48 h followed by MTT assay (63). Void nanoparticles made from F-
127 were used as control. IC50 values were interpolated and normalized based on the loading capacity 
data. 
2.4.  Cellular Uptake Studies 
Sub-confluent MDA-MB-231 cells were passaged and seeded at 80,000/200 µL cells per well in 24 
well plate and allowed to adhere for 2 days. After 2 days, medium was renewed with 5%FBS RPMI for 
30 minutes. Cells were treated with Aln-Cur-NPs, Cur-NPs and raw curcumin at 10 µM concentration 
equivalent to curcumin and PBS (negative control) for 24 h. Next day, all wells were washed three times 
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with 100 µL of PBS. Cells were fixed using 4% formaldehyde. Triton-X 100 was used to permeabilize 
the cells. Hoechst labelling solution was used for staining the nuclei. Washing was repeated to remove 
Hoechst solution. The slides were mounted with mounting media and viewed under Leica spe-ll 
confocal laser scanning microscope at Bosch Institute, The University of Sydney. Curcumin is 
naturally fluorescent in the green spectrum. 
2.5. Live Cell Imaging: 
IncuCyte® Zoom & S3 Live-Cell Analysis System (Essen Bioscience, USA) were used to examine the 
cytotoxic effect and uptake of NPs by MDA-MB 231 cell lines in two independent experiments. The 
uptake of NPs was determined depending on the natural fluorescence of curcumin which can be detected 
in the green channel of IncuCyte® S3. MDA-MB 231 cells were seeded at 9000 cells/well in a flat-
bottomed 96 well plate and allowed to adhere for 24 h. Cells were treated with Cur-NP, Aln-Cur-NP 
and raw curcumin in triplicates and at concentrations of 12.5, 25, 50 µM based on the amount of 
equivalent curcumin. PBS was used as a negative control. Time lapse images were taken using 20x 
magnification power at 2 h intervals for 48 h.  
In another experiment, the effects of our NPs on cell viability was determined against MDA-MB-231 
cell lines using IncuCyte® Zoom. MDA-MB-231 cells were seeded at 2000 cells/well and were allowed 
to adhere overnight. Cur-NP, Aln-Cur-NP, Raw curcumin at their IC50 concentrations (obtained from 
MTT studies) were added to the wells. Cytotoxic effect was determined over the period of 3 days. 
2.6.  PTHrP ELISA Assay  
PTHrP ELISA assay was performed using Human PTHLH® (Human Parathyroid Hormone-related 
Protein) ELISA kit, 96 tests (Fine Test). Sub-confluent human breast cancer MDA-MB-231 cells were 
plated at 5X104 cells per well (n=2) in 96 well plate and allowed to adhere for 24 h. Next day, cells were 
preincubated in 80 µL of medium and with 20 µL of Cur, Cur NP and Aln-Cur-Np at IC25 and IC50 
concentrations (based on MTT assay results) for 4 h. Medium was then refreshed with the addition of 
100 µL of recombinant human TGF-β1 (5 ng/mL) for 24 h. Samples were diluted by addition of 50 µL 
of supernatant to 75 µL of sample dilution buffer in Eppendorf tubes. Cell culture supernatant was 
centrifuged for 20 minutes to remove insoluble impurities and cell debris at 1000×g at 2 - 8°C. Clear 
supernatant was collected and used in the assay immediately. ELISA plate wells were washed 2 times 
before adding standard, sample and control wells. After that all ELISA assay steps were done according 
to manufacturer’s instructions. At the end ELISA plate was read using microplate reader at 450nm 
immediately.  
3. Results 
3.1. Determination of loading capacity 
Loading capacity for new batches of Aln-Cur-NPs (batch #3) and Aln-Cur-NPs (batch #4) was found 
to be 4% and 3.7% respectively. Loading capacity for Cur-NPs was found to be 5.7%. Loading 
capacity of Cur-NPs was higher than Aln-Cur-NPs (Fig. 2.4). 
 
 
 
 
 
Nano-particles Interpolated 
Values 
Loading 
Capacity 
Encapsulation 
Efficiency 
 
Aln-Cur-NPs#3 
Aln-Cur-NPs#4 
Cur-NPs 
39.5 µg/ml 
36.7 µg/ml 
57 µg/ml 
4% 
3.7% 
5.7% 
80% 
74% 
57% 
44 
 
 
 
                Fig. (2. 4): Loading Capacity (%) of two batches of alendronate-conjugated curcumin-loaded nanoparticles. 
3.2. Schematic Representation of Aln-Cur-NP 
Figure 2.5 represents scheme for formation of Aln-Cur-Nanoparticles. 
 
 
      Fig. (2.5): Schematic representation of formation of Aln-Cur-Nanoparticles. 
3.3.  In vitro anticancer activities of curcumin nanoparticles 
Aln-Cur-NPs and Cur-NPs were studied for their direct antiproliferative properties on three breast 
cancer cells, MCF-7, MDA-MB-231 and SK-BR-3 (Table 2.1).  
Table 2.1. IC50 values obtained against breast cancer cells 
 
 
 
 
MCF-7  
  
NP or Control IC50 (µg/mL) 
NP or control IC50 (µg/mL) 
Aln-Cur NPa 13.9 ± 1.6 
Cur-NPb 31.0 ± 4.0 
Void NPc >1000 
 
 
 
MDA-MB-231  
NP or control IC50 (µg/mL) 
Aln-Cur NP 22.2 ± 4.8 
Cur-NP 51.6 ± 21.7 
Void NP >1000 
 
 
 
SK-BR-3 
 
NP or control IC50 (µg/mL) 
Aln-Cur NP 7.7 ± 2.5 
Cur-NP 61.6 ± 10.9 
Void NP >1000 
aalendronate-conjugated curcumin nanoparticles, bcurcumin nanoparticles, c void nanoparticles. 
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Fig. (2.6). Comparison between the in vitro antitumor activity of alendronate-conjugated (Aln-Cur-NPs) vs. unconjugated NPs 
(Cur-NPs). Two Way ANOVA, Dunnett's Post Hoc multiple comparisons test. * P<0.05, ** P<0.01 and *** P<0.001 when 
compared with Cur-NP (mean + SD). 
 
Antitumor activity of the raw curcumin and curcumin nanoparticles with/without alendronate 
conjugation is shown as IC50 values in Table 2.1. A higher antitumor activity was observed for Aln-
Cur-NP as compared to Cur-NP with IC50 values obtained at 13.9, 22.2 and 7.7 µg/mL for MCF-7, 
MDA-MB-231 and SK-BR-3, respectively. IC50 values greater than 1000 µg/mL for void nanoparticles 
indicate that there was no adverse effect of the polymer alone against tested cancer cell lines. Figure 5 
demonstrates a comparison between Aln-Cur-NPs and Cur-NPs. This suggests that the addition of 
alendronate to the formulation enhanced the anti-cancer properties of the NPs, which indicates the 
hypothesis of curcumin/bisphosphonates combination synergistic effect. 
 
3.4. Cellular internalization by confocal laser scanning microscopy (CLSM) 
In vitro nanoparticles uptake and drug internalization were evaluated using CLSM in MDA-MB-
231 breast cancer cells after 24 h of drug treatment. Preliminary studies were done to optimize 
nanoparticles concentration and incubation times (data not shown). Curcumin is  auto-fluorescent 
in nature. Cellular internalization is shown in the form of green fluorescence intensity. Cellular 
internalization of Aln-Cur-NPs and Cur-NPs to MDA-MB-231 cell lines was found to be more 
than raw curcumin. MDA-MB-231 cancer cells treated with raw curcumin were shown to achieve 
weaker fluorescence intensity, i.e. less drug uptake was noticed. In the negative control group 
(PBS), no green fluorescence was detected (Fig.  2.7). We also performed quantitative analysis 
which confirmed statistically significant increase in the uptake of curcumin in both NPs forms as 
compared to raw curcumin (Fig. 2.8). However, there was no statistically significant difference 
between the two different NPs, Aln-Cur-NPs and Cur-NPs. 
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  FITC Channel (For Drug)   Hoechst Channel (For 
nucleus) 
Overlay Image 
Raw 
curcumin 
 
 
 
 
 
 
 
 
 
 
 
Cur-NP 
 
 
 
 
 
 
 
 
 
 
Aln-Cur-
NP 
 
 
 
 
 
PBS 
 
   
Fig. (2. 7). Cellular internalization of curcumin in MDA-MB-231 cancer cells after treating the cells at 10 µM concentration. 
Confocal Laser Scanning microscopy images. Cells were incubated with nanoparticles for 24 hours at 37°C in MDA-MB-231 
cell lines. Curcumin appears in green fluorescence, nuclei appear in blue fluorescence and overlay appear as combination of 
green and blue image.   
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Fig. (2. 8): Statistical analysis of uptake of Aln-Cur-NP and Cur-NPs by MDA-MB-231 cancer cells as compared to raw 
curcumin showed there is significant difference between uptake of NPs and raw curcumin, while no significant difference was 
observed in the uptake of Aln-Cur-NPs and Cur-NPs. * P<0.05, ** P<0.01, *** P<0.001 and **** P<0.0001. 
6.3 Live cell imaging  
The results of IncuCyte® S3 and IncuCyte® Zoom  live cell imaging clearly showed a significant 
uptake of nanoparticles by MDA-MB-231 cells. The uptake of raw curcumin was much less than 
the two NP forms, and it could be mostly seen outside the cells (green dots) whereas the 
nanoparticles were detected inside the cells (Fig. 2. 9A and Fig. 2.9B). Furthermore, a lower 
viability was observed by the Aln-Cur-NP-treated cells as compared to Cur-NP-treated cells and 
raw curcumin. One important finding was that curcumin inside nanoparticles converted to 
curcumin crystals after they had killed the cells. More crystals were observed with Aln -Cur-NPs 
as compared to Cur-NPs. 
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Fig. (2. 9A). IncuCyte®S3 images comparing the uptake of Cur-NP, Aln-Cur-NP and raw curcumin at 1h, 3h, and 48 h after 
adding the drug at 12.5 µM concentration based on the amount of equivalent curcumin. 
  
 
 
 
 
 
 
 
 
 
 
 
 
49 
 
 
 
 
Day 0, 8:00 Image Day 2, 20:00 Image Day 3, 12:00 Image 
Raw 
curcumin 
 
 
 
 
 
 
 
Cur-NP 
 
 
 
 
 
 
Aln-Cur-
NP 
 
 
 
 
 
 
 
 
PBS 
  
 
 
  
Fig. (2. 9B). IncuCyte®Zoom images comparing the cytotoxicity of raw curcumin, Cur-NP, Aln-Cur-NP over the period of 3 
days after adding the drug at IC50 concentration. 
6.3.  PTHrP ELISA Assay  
Effect of nanoparticles on the release of PTHrP by MDA-MB-231 cells was determined after 24 h of 
treatment. TGF-β was also added to stimulate the release of PTHrP by MDA-MB-231 cancer cells. Aln-
Cur-NPs, Cur-NPs, raw curcumin were used at IC25 and IC50 concentrations. At the end of experiment 
absorbance was measured using microplate reader at 450 nm. The amount of PTHrP released by MDA-
MB-231 cells treated with Aln-Cur-NP at IC50 and IC25 concentrations equivalent of curcumin was 
reduced to 152.6 pg/mL and 137.4 pg/mL, respectively, compared to the negative control (PBS) at 
above 1669.2 pg/mL. Cancer cells treated with Cur-NPs at IC50 and IC25 concentrations, reduced the 
release of PTHrP to 217.4 pg/mL and 141.1 pg/mL, respectively. Raw curcumin also showed some 
inhibitory effect on release of PTHrP by MDA-MB-231 cancer cell lines with values equal to 189.7 
pg/mL and 330.3 pg/mL IC50 and IC25 concentration (Fig. 2.10).  
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Fig. (2.10). Effect of curcumin (C-IC50, C-IC25), curcumin nanoparticles (Cur-NP IC50, Cur-NP IC25), alendronate 
nanoparticles (Aln-Cur-NP IC50 and IC25) and PBS on the release of PTHrP in MDA-MB-231 cells was determined using 
Human PTHLH (Parathyroid hormone-related protein) ELISA kit (Fine Test).  
 
Results clearly showed nanoparticles have reducing effect on release of PTHrP from MDA-MB-231 
cells as compared to the negative control (PBS). Aln-Cur-NP showed maximum reducing effect on 
PTHrP release from MDA-MB-231 cells.  
Discussion 
In this study, we investigated the biological behavior of curcumin nanoformulations with and without 
alendronate conjugation for the prevention and treatment of breast cancer bone metastasis. Curcumin 
is extracted from rhizome of Curcuma longa and is a widely studied molecule (64). It has cytotoxic, 
anti-oxidant, anti-proliferative potential. However, the challenge with its application as a medicine is 
the poor bioavailability due the very low solubility in water.  Curcumin has poor absorption, 
biodistribution and bioavailability. Most of the curcumin get metabolized in the intestine and 
liver which result in a rapid degradation and elimination from the body. Two major pathways 
identified in curcumin metabolism in the intestine are O-conjugation (form to form curcumin 
glucuronide and curcumin sulfate) and reduction (to form tetrahydrocurcumin, 
hexahydrocurcumin, and hexahydrocurcuminol) (65, 66). Curcumin may also undergo 
intensive second metabolism in the liver. The major metabolites are glucuronides of 
tetrahydrocurcumin and hexahydrocurcumin, with dihydroferulic acid and traces of ferulic acid 
as further metabolites (65, 66). Most of elimination occurs through feces and negligible amount 
of curcumin is excreted in the urine. 
We used a nanoformulation strategy to improve the solubility and poor stability of curcumin. 
Nanoformulation has been shown to be a strategy to improve the antitumor properties of curcumin in 
against breast, prostate, cervical and pancreatic cancer cells (67-69). Bisphosphonates are a class of 
drugs that are used for osteoporosis to prevent bone loss. Bisphosphonates are characterized as 
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compound having double C-P bonds. Bisphosphonates have high affinity for the hydroxyapatite of the 
bone. Bone will selectively uptake bisphosphonates in two steps 1) first due to the bone resorption effect 
of osteoclasts, hydroxyapatite crystals are exposed (physicochemical action) and 2) bisphosphonates 
get attracted towards hydroxyapatite of the bone and are uptaken by osteoclasts and inhibit bone 
resorption (cellular effect) (70). All bisphosphonates possess common P-C-P bond. The only difference 
is in their side chain which produces different chemical structures for bisphosphonates (71).  
Preclinical data suggested that bisphosphonates may also reduce cell viability and proliferation by 
increasing apoptosis in tumor cells. They may also possess anti-angiogenesis, anti-neoplastic and 
immunomodulatory effects. Bisphosphonates can also decrease tumor cell adhesion and invasion (72, 
73). Due to anti-osteoclastic properties of bisphosphonates, they are potent inhibitors of bone resorption. 
Other mechanism for their direct inhibition of cancer cells growth might be their anti-angiogenic 
potential (74). In many studies, alendronate has been proved to exert anti-proliferative effects against 
different cancer cells such as breast, myeloma, neuroblastoma and melanoma (75).  
Recently, polymeric micelles have been  widely investigated as  promising anticancer drug 
delivery carriers (76, 77). Drugs encapsulated in micelles have been shown to have a more 
accumulation in solid tumors in comparison with free drugs. This increased accumulation of 
drug might be because of enhanced permeability and retention effect (EPR). Pluronic acid (Fig. 
2.11) is the most widely used polymeric vehicle for micelle formation. It is highly compatible 
with biological fluids. Pluronic acid is a triple block structure comprised of poly(ethylene oxide 
(PEO)) and poly(propylene oxide)(PPO)) chains. PEO segment of F-127 is hydrophilic in 
nature while PPO segment is hydrophobic. PPO segment incorporates hydrophobic drugs. Due 
to the self-assembly nature of F-127, it forms spherical core at critical micelles concentration 
(CMC) (78). CMC for F-127 is about 0.26-0.8wt% (79) and we have previously optimized the 
ratios of curcumin to F127 within this CMC range to achieve the best particle size and stability 
(data under publication).   
 
 
 
Fig. (2.11). Chemical structure of F-127 
In our study, we have conjugated curcumin nanoparticles with alendronate aiming to achieve synergistic 
anticancer in addition to anti-bone resorption effect. It was proposed that alendronate not only target 
curcumin nanoparticles to the bone but also will exert some direct anti-bone resorption and cytotoxic 
effect in combination and synergistic effect with curcumin. 
We have formulated two new batches of Aln-Cur-NPs.  Loading capacity for Aln-Cur-NPs is 4 % and 
3.7 % while for Cur-NPs it is 5.7 %. Nanomicelles proved to increase water solubility.  
The effect of Aln-Cur-NPs and Cur-NPs was also determined on the proliferation of MDA-
MB-231, MCF-7 and SK-BR-3 cells through cell viability MTT assay. Mitochondrial 
reduction of MTT in three breast cancer cells by Aln -Cur-NPs and Cur-NPs was found to 
occur in a dose dependent manner. We compared the antiproliferative activity and IC 50 values 
of Aln-Cur-NPs and Cur-NPs with raw curcumin and void-NPs. Increased antiproliferative 
effect of Aln-Cur-NPs relative to Cur-NPs and raw curcumin, indicated the direct inhibitory 
effect of alendronate when it is in combination with curcumin in the micellar formations. 
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Curcumin was released from nanomicelles in the form of crystals after being used by the 
cells. In previous studies, it was shown that following cell death due  to curcumin’s effect, 
curcumin was first precipitated out as amorphous nanospheres. Amorphous nanospheres then 
aggregated to form needle shaped crystals (80). In our experiments we showed that the 
amorphous form of curcumin which was loaded in the nanoparticles was the effective 
form.  
Cellular internalization of nanomicelles was determined using CLSM. CLSM provides 
exciting opportunities for imaging nanomicelles internalization into breast cancer cells. 
CLSM has capacity to reject out-of-focus light and provides sharp and high-contrast images 
of cells (81). Curcumin is auto-fluorescent in nature. The internalization of curcumin by 
MDA-MB-231 cells at concentration of 10µM equivalent to curcumin after 24 h of treatment 
was observed for Aln-Cur-NPs and Cur-NPs and raw curcumin. Curcumin showed green 
fluorescence in the images obtained with CLSM, suggesting the curcumin  is released from 
nanomicelles. The cell’s nucleus was counterstained with Hoechst labelling solution and was 
appeared as blue in CLSM images. While curcumin appeared as bright green signals in CLSM 
images. Brighter green signals were noticed in MDA-MB-231 cells treated with Aln-Cur-NPs 
compared to cells treated with Cur-NPs while much less green signals were observed for 
MDA-MB-231 cells treated with raw curcumin and no green signals were observed in the 
negative control. This indicated that in both nanomicelle-treated cells there is a higher 
amount of curcumin.  
In two different experiments the effect of nanoparticles on live cells was examined using 
IncuCyte. The uptake of Cur-NPs and Aln-Cur-NP was more than raw curcumin. While no 
significant difference was observed in uptake of Cur-NP and Aln-Cur-NP. These results from 
IncuCyte were in line with our quantitative analysis performed using confocal images. The 
nonsignificant difference in the uptake of Cur -NPs and Aln-Cur-NP indicates that the higher 
cytotoxic effect of Aln-Cur-NPs on MDA-MB-231 cells confirmed by both MTT and 
IncuCyte is due to the synergistic effect of alendronate and curcumin.  
PTHrP exerts its action by acting via PTHrP receptors (PTHrP-R). It is a protein that mediates autocrine 
(secreted and acted on the same cell through autocrine receptors) and paracrine (secreted by cell and 
acts on neighboring cells) functions (82). On the bone, PTHrP exerts its effect through endocrine action 
(83, 84). PTHrP has role in development of normal breast growth and physiology. PTHrP released by 
epithelial cells contributes to the development of breast in embryos (85). In adult’s breast, myoepithelial 
cells release PTHrP and it acts on periductal stroma and inhibits ductal extension. During lactation, 
PTHrP secreted by alveolar epithelial into maternal circulation and stimulates milk production (86). 
PTHrP is produced by tumor cells and promotes osteoclastic activity and osteolytic bone metastasis 
(87). The role of PTHrP in the development of primary tumor is not clear. About 60% of primary breast 
cancer patients and 70% of patients with bone metastases have increased PTHrP levels. A higher PTHrP 
and mRNA 1-139 expression is correlated with the development of invasive bone metastasis (83). 
Tumor-derived PTHrP stimulates vicious cycle for bone metastasis. It also stimulates tumor cell 
adhesion, proliferation and survival (88). During osteolytic resorption, TGF-β is released by bone 
matrix. TGF-β stimulates the release of PTHrP from tumor cells (89). Then PTHrP causes bone 
resorption and stimulates vicious cycle for bone metastasis (83). Results of a study revealed that 
knocking down of PTHrP in MDA-MB-231 cells could be a potential treatment option for breast cancer 
and skeletal metastasis. Knocking down of PTHrP stimulates different mechanisms like, decrease in A1 
proteins & cyclins D1 levels, increase in levels of LC3-II & Beclin 1, autophagosomes formation, 
cleavage of caspase 8 and induced tumor cells apoptosis. All these processes can inhibit tumor growth 
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and hence skeletal metastasis (90). Curcuminoids are proved to have inhibitory effect on PTHrP 
secretion by MDA-MB-231 cells (91) and also prevent TGf-β induction of PTHrP (92). In our study, 
the effect of our nanoparticles (Aln-cur-NPs and Cur-NPs) at IC50 and IC25 concentrations showed a 
decrease in the release of PTHrP by MDA-MB-231 cells. Alendronate has proved to have cytotoxic 
effect (93). Aln-Cur-NPs and Cur-NPs showed the highest reducing effects on release of PTHrP by 
MDA-MB-231 cells. While with cells treated with PBS, a high concentration of PTHrP was released 
by MDA-MB-231 cells. These results are in line with previous reports on the preventative effects of 
curcumin on the secretion of PRHrP in breast cancer cells, which results in the inhibition of bone 
resorption activation (55). 
Conclusion 
Curcumin was encapsulated in pluronic F-127 nanoparticles. Alendronate not only made our 
formulation targeted to the bone, but it also synergized the anticancer activity. The results of MTT assay 
confirmed the anticancer effect of Aln-Cur-NPs on different cancer cells. CLSM images confirmed the 
uptake of nanoparticles by MDA-MB-231 cells. The uptake and cytotoxicity of NPs was confirmed by 
IncuCyte®. The results of PTHrP ELISA confirmed the inhibitory effect of Aln-Cur-NPs on release of 
PTHrP by MDA-MB-231 cells and can be evaluated by in-vivo studies. 
In conclusion, our results showed that alendronate-conjugated curcumin nanoparticles are promising 
candidate for in-vivo studies for enhanced anticancer effect of curcumin in breast cancer bone 
metastases.  
We are hoping to develop a promising targeted drug to prevent breast cancer bone metastases 
with less side effect profile as compared to conventional therapy.  
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CHAPTER 4 
CONCLUSIONS, FUTURE DIRECTIONS & FINAL 
REMARKS 
 The advent of nanotechnology opened a new horizon in direct targeting of cancer cells without 
harming the normal cells. This thesis research tried to fill a gap of lack of preventive therapy 
for breast cancer bone metastases. Different experiment performed with Alendronate 
conjugated nanoparticles shown promising results in preventive and treating breast cancer bone 
metastases. Loading capacity determination showed the efficient loading of curcumin into 
nanoparticles. Antiproliferative activities of Aln-Cur-NPs was found to be better than Cur-NPs 
in MDA-MB-231, MCF-7 and SK-BR-3 cancer cells. CLSM verified the uptake of NPs by 
MDA-MB-231 cancer cells. PTHrP assay showed the inhibitory effect of Aln-Cur-NPs on 
release of PTHrP peptide and hence inhibition of bone metastases. We conclude that this 
combination of Aln and curcumin has shown synergistic effect on killing cancer cells. This 
synergistic effect is because of alendronate itself effect on cancer cells and bone and cytotoxic 
effect of curcumin.   
 
FUTURE DIRECTIONS 
The results obtained validate the efficacy of Aln-Cur-NPs as compared to raw curcumin and 
Cur-NPs.  
In future we may investigate the affinity of Aln-Cur-NPs for bone and evaluate its effect on 
bone-resorption.  
Our promising results may also point towards the in vivo biological evaluation of alendronate 
conjugated curcumin nanoparticles to prevent breast cancer bone metastases.  
 
FINAL REMARKS 
We anticipate the alendronate conjugated curcumin nanoparticles developed in our project has 
great potential to prevent breast cancer bone metastases. There is a strong need to evaluate this 
research more in in vivo studies. 
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